Skip to main content
Signal8

Surgery Partners, Inc. Announces Third Quarter 2026 Results

$SGRYPress releaseNov 9, 2026, 4:10 PM ET

Surgery Partners reported Q3 2026 revenue of $815.3 million, down 0.8% year-over-year on the Idaho Falls divestiture, with a $21.1 million net loss attributable to shareholders and Adjusted EBITDA of $132.7 million versus $136.4 million a year ago. Underlying momentum was solid: same-facility revenues rose 6.0% on a 5.8% increase in revenue per case, and year-to-date revenue grew 2.1% to $2,475.1 million. The bigger news is an amended merger agreement with HealthSpan Partners that raises consideration to $25.00 per share in cash — an enterprise value of up to ~$6.0 billion — following an unsolicited competing proposal.

Key figures

Revenue
815300000
Guidance
Guidance withdrawn; no earnings call due to pending merger
Deal Value Usd
6000000000
Cash
354500000
Ticking fee rate
10% per annum on $25.00 per share after March 1, 2027
Adjusted ebitda q3
132700000
Net debt to ebitda
4.4
Adjusted ebitda ytd
360200000
Merger price per share
25
Operating cash flow q3
103500000
Same facility cases growth q3
0.2%
Same facility revenue growth q3
6.0%

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    SGRY: Surgery Partners, Inc. Announces Third Quarter 2026 Results — AI Analysis | Signal8